Efficacy News and Research

RSS

Efficacy of antibodies induced by natural infection, vaccination, or both against SARS-CoV-2 Omicron and Beta variants

A study has demonstrated that antibodies induced by two-dose COVID-19 vaccination or natural infection exhibit very low neutralizing activity against the omicron variant of SARS-CoV-2.

4 Jan 2022

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

An independent study confirms that current and prospective antiviral treatments are effective in inhibiting severe infection from SARS-CoV-2.

4 Jan 2022

The impact of natural selection on sequence diversity in SARS-CoV-2

Recent genomic analysis demonstrates that the SARS-CoV-2 genome is under two distinct selective forces.

3 Jan 2022

Researchers identify a biomarker in platelets that tracks the extent of depression

Researchers are one step closer to developing a blood test that provides a simple biochemical hallmark for depression and reveals the efficacy of drug therapy in individual patients.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

Researchers investigate the ability of immunity acquired from SARS-CoV-2 wild-type infection to protect against the Omicron variant in Syrian hamster models.

3 Jan 2022

Omicron surges in England especially in young

Researchers used data from the REACT-1 study to analyze SARS-CoV-2 community prevalence and the emergence of the Omicron variant in England.

3 Jan 2022

Echinacea, a potent antiviral against SARS-CoV-2

Researchers present available evidence on the activity of Echinacea purpure against coronavirus infections.

3 Jan 2022

Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity

A team of investigators have discovered a genomic variant that may help clinicians predict which patients will experience cardiotoxicity from a widely used chemotherapy drug, according to a Northwestern Medicine study published in Circulation.

3 Jan 2022

New systematic review finds low-quality evidence on the effectiveness of hangover remedies

A new systematic review has found only very low-quality evidence that substances claiming to treat or prevent alcohol-induced hangover work.

3 Jan 2022

Engineer receives $2.1 million grant to test a treatment strategy for children with cerebral palsy

Mechanical engineer and inventor Zach Lerner, assistant professor in Northern Arizona University's Department of Mechanical Engineering, has been awarded $2.1 million by the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health & Human Development.

3 Jan 2022

WHO lists the Comirnaty COVID-19 mRNA vaccine for emergency use

The World Health Organization today listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive emergency validation from WHO since the outbreak began a year ago.

2 Jan 2022

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

A reliable assessment of COVID-19 vaccine protection duration

Researchers from the University of North Carolina, University of Washington, and the US Food and Drug Administration propose fitting a Cox model with two time indexes, the event times measured from the start of the study in calendar time and the log hazard for the vaccine effect.

30 Dec 2021

How much do mutations reduce vaccine effectiveness in the Omicron variant?

In new research, scientists from Adaptive Biotechnologies have been investigating the impact of spike protein mutations on vaccine efficiency for the Omicron variant. The study is currently available on the medRxiv* preprint server while awaiting peer review.

30 Dec 2021

SARS-CoV-2 infection and immunity in pregnancy and fetal development

A review conducted by a team of researchers from the Icahn School of Medicine at Mount Sinai, the University of Colorado, and Active Motif, Incorporated compiles information on SARS-CoV-2 virology, in utero transmission from infected pregnant mothers to fetuses, new findings on possible methods of SARS-CoV-2 cellular trafficking through exosomes, and the transcriptomic effects of SARS-CoV-2 infection, in order to inform future studies aimed at a better understanding of COVID-19 and the development of therapeutic solutions against SARS-CoV-2.

30 Dec 2021

Factors associated with SARS-CoV-2 breakthrough infection in fully vaccinated individuals

New study findings showed that the SARS-CoV-2 breakthrough infections are rare and show mild or asymptomatic profiles generally. The breakthrough infection occurs early after vaccination in almost 50% of the cases within 70 to 80 days post full vaccination.

30 Dec 2021

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.

30 Dec 2021

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

Researchers evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with inflammatory bowel disease.

30 Dec 2021

Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

New research suggests convalescent plasma from unvaccinated donors is not effective against the Omicron variant, however, “hybrid” convalescent plasma from donors who recovered from COVID-19 infection and are vaccinated provides considerable antibody protection.

29 Dec 2021

Efficacy News and Research

Efficacy of antibodies induced by natural infection, vaccination, or both against SARS-CoV-2 Omicron and Beta variants

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

The impact of natural selection on sequence diversity in SARS-CoV-2

Researchers identify a biomarker in platelets that tracks the extent of depression

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

Omicron surges in England especially in young

Echinacea, a potent antiviral against SARS-CoV-2

Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity

New systematic review finds low-quality evidence on the effectiveness of hangover remedies

Engineer receives $2.1 million grant to test a treatment strategy for children with cerebral palsy

WHO lists the Comirnaty COVID-19 mRNA vaccine for emergency use

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A reliable assessment of COVID-19 vaccine protection duration

How much do mutations reduce vaccine effectiveness in the Omicron variant?

SARS-CoV-2 infection and immunity in pregnancy and fetal development

Factors associated with SARS-CoV-2 breakthrough infection in fully vaccinated individuals

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News